Targeting Pathophysiologic Pathways in Cervical Cancer: Why Immunotherapy?

Program Overview

This 15-minute infographic activity uses an interactive approach augmented by a whiteboard animation and clinician videos to delineate immunotherapy rationale, mechanism of action, and safety considerations in cervical cancer.

Credit Expired

Target Audience

This activity is intended for oncology, pathology, gynecologic oncology, and OB/GYN clinicians (MD/DO/NP/PA) who treat patients with cervical cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Align the mechanism of action of immune checkpoint inhibitors with underlying cervical cancer processes

Activity Faculty

Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

Professor and Division Director
Division of Gynecologic Oncology
University of California
Irvine, CA

Featured RMEI CE Activities – Earn CE Credit(s)

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

1.25 CE Credit(s)

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

1.0 CE Credit(s)

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

0.75 CE Credit(s)

Privacy | Terms of Use